In patients with moderate to severe psoriasis who also have obesity or type 2 diabetes, what is your approach to counseling them on the potential role of adjunctive GLP-1 receptor agonists in reducing overall psoriasis disease burden?

I am a firm believer that these medications are key to maximizing therapeutic response in diseases like psoriasis and even more so in HS. They have been shown to reduce the production of inflammatory markers in both diseases. The Together PsO and PsA trials showed better PASI responses (including PA...